EconPapers    
Economics at your fingertips  
 

NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests

James F. O’Mahony, Mike Paulden and Christopher McCabe

Open Access publications from School of Economics, University College Dublin

Abstract: The National Institute of Health and Care Excellence (NICE) recently published a review of discounting practice and theory as part of a consultation on its current methods guidelines. The review examines the case for revision or retention of current methods. The changes considered include eliminating favourable rates in certain special cases and the reduction of the base-case rate for costs and health effects from 3.5 to 1.5%. The review also notes the potential need to reduce the cost-effectiveness threshold to accommodate a discount rate reduction, explaining that an agreement between the UK government and the pharmaceutical industry proscribes changing NICE's threshold range until the end of 2023. We believe NICE should be commended for a useful overview of the existing literature and relevant issues. We firmly endorse NICE's view that favourable discount rates are not a good way to apply a preference for certain interventions. Similarly, we support the option of reducing the discount rate to 1.5%, which better accords with real government borrowing costs. We suggest further work to clarify the appropriate theoretical basis for the NICE's social discount rate and the sensitivity of the threshold to changes in discounting. The prospects of a necessary discount rate reduction appear to depend on whether a threshold reduction can be achieved within NICE's current range or if the range itself must be revised downwards. NICE has usefully informed the debate around discount rates. Ultimately, the path to a methodologically consistent and evidence-based revision of discounting depends on whether NICE needs to adjust the threshold too and if it is free to do so.

Keywords: National Institute of Health and Care Excellence (NICE); Discounting practices; Vaccine assessment guidelines; Pharmaceutical manufacturers (search for similar items in EconPapers)
Pages: 8 pages
Date: 2021-01
References: Add references at CitEc
Citations:

Published in: PharmacoEconomics, 39(2) 2021-01-19

Downloads: (external link)
http://hdl.handle.net/10197/25005 Open Access version, 2021 (application/pdf)
Our link check indicates that this URL is bad, the error code is: 405 Not Allowed (http://hdl.handle.net/10197/25005 [302 Found]--> https://researchrepository.ucd.ie/handle/10197/25005)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ucn:oapubs:10197/25005

Access Statistics for this paper

More papers in Open Access publications from School of Economics, University College Dublin Contact information at EDIRC.
Bibliographic data for series maintained by UCD School of Economics ().

 
Page updated 2026-11-13
Handle: RePEc:ucn:oapubs:10197/25005